Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

被引：0

作者：

Pullarkat, Vinod ^{[1
,2
]}

Pratz, Keith W. ^{[3
]}

Doehner, Hartmut ^{[4
]}

Recher, Christian ^{[5
]}

Thirman, Michael J. ^{[6
]}

Dinardo, Courtney D.

Fenaux, Pierre ^{[8
,9
]}

Schuh, Andre C. ^{[10
]}

Wei, Andrew H. ^{[11
,12
]}

Pigneux, Arnaud ^{[13
]}

Jang, Jun-Ho ^{[14
]}

Juliusson, Gunnar ^{[15
]}

Miyazaki, Yasushi ^{[16
]}

Selleslag, Dominik ^{[17
]}

Arellano, Martha L. ^{[18
]}

Liu, Chenglong ^{[19
]}

Ridgeway, Jean A. ^{[19
]}

Potluri, Jalaja ^{[19
]}

Schuler, Jovita ^{[19
]}

Konopleva, Marina ^{[7
]}

机构：

[1] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[2] City Hope Comprehens Canc Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA 91010 USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[4] Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany

[5] CHU Toulouse, Toulouse, France

[6] Univ Chicago Med, Dept Med, Sect Hematol Oncol, Chicago, IL USA

[7] Montefiore Einstein Comprehens Canc Ctr, Bronx, NY USA

[8] Hop St Louis, Assistance Publ Hop Paris, Paris, France

[9] Univ Paris, Paris, France

[10] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

[11] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Peter MacCallum Canc Ctr, Melbourne, VIC, Australia

[12] Univ Melbourne, Melbourne, VIC, Australia

[13] CHU Bordeaux, Dept Hematol, Bordeaux, France

[14] Sungkyunkwan Univ, Samsung Med Ctr, Dept Hematol Oncol, Sch Med, Seoul, South Korea

[15] Skane Univ Hosp, Dept Hematol, Lund, Sweden

[16] Nagasaki Univ, Atom Bomb Dis Inst, Dept Hematol, Atom Bomb Dis & Hibakusha Med Unit, Nagasaki, Japan

[17] Algemeen Ziekenhuis St Jan, Brugge, Belgium

[18] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[19] AbbVie Inc, N Chicago, IL USA

来源：

BLOOD CANCER JOURNAL | 2025年 / 15卷 / 01期

关键词：

D O I：

10.1038/s41408-025-01263-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：5

共 50 条

[41] Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment
Naka, Ryosuke
Kondo, Tadakazu
Nishikubo, Masashi
Muranushi, Hiroyuki
Ueda, Yasunori
Oka, Tomomi
Wada, Fumiya
Kanda, Junya
Yamamoto, Shohei
Watanabe, Mitsumasa
Okada, Shinri
Imada, Kazunori
Nakabo, Yukiharu
Mizutani, Yu
Nannya, Yasuhito
Ogawa, Seishi
Ishikawa, Takayuki
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (09) : E251 - E254
[42] Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome
Chua, Chong Chyn
Fleming, Shaun
Wei, Andrew H.
[J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (01) : 3 - 12
[43] SINGLE INSTITUTION EXPERIENCE OF 5-AZACITIDINE THERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
Freyrie, A.
Guidotti, F.
Reda, G.
Binda, F.
Cortelezzi, A.
[J]. HAEMATOLOGICA, 2012, 97 : 587 - 587
[44] Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
Patel, Kishan K.
Zeidan, Amer M.
Shallis, Rory M.
Prebet, Thomas
Podoltsev, Nikolai
Huntington, Scott F.
[J]. BLOOD ADVANCES, 2021, 5 (04) : 994 - 1002
[45] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Yamamoto, Kazuhito
Shinagawa, Atsushi
DiNardo, Courtney D.
Pratz, Keith W.
Ishizawa, Kenichi
Miyamoto, Toshihiro
Komatsu, Norio
Nakashima, Yasuhiro
Yoshida, Chikashi
Fukuhara, Noriko
Usuki, Kensuke
Yamauchi, Takahiro
Asada, Noboru
Asou, Norio
Choi, Ilseung
Miyazaki, Yasushi
Honda, Hideyuki
Okubo, Sumiko
Kurokawa, Misaki
Zhou, Ying
Zha, Jiuhong
Potluri, Jalaja
Matsumura, Itaru
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
[46] Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes
Montalban-Bravo, Guillermo
Short, Nicholas J.
Chien, Kelly S.
Valero, Yesid Alvarado
Daver, Naval
Borthakur, Gautam
Swaminathan, Mahesh
Maiti, Abhishek
Hammond, Danielle E.
Nogueras-Gonzalez, Graciela
Huang, Xuelin
Schneider, Heather
Shelly, Kristen
Kadia, Tapan M.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
[J]. BLOOD, 2023, 142
[47] Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine
Arana-Yi, Cecilia
Block, AnneMarie W.
Sait, Sheila N.
Ford, Laurie A.
Barcos, Maurice
Baer, Maria R.
[J]. LEUKEMIA RESEARCH, 2008, 32 (07) : 1043 - 1048
[48] Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodisplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Reda, Gianluigi
Riva, Marta
Cassin, Ramona
Fattizzo, Bruno
Pennisi, Martina
Giannarelli, Diana
Molteni, Alfredo
Freyrie, Alessandra
Cairoli, Roberto
Cortelezzi, Agostino
[J]. BLOOD, 2016, 128 (22)
[49] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
Savona, M. R.
Kolibaba, K.
Conkling, P.
Kingsley, E. C.
Becerra, C.
Morris, J. C.
Rifkin, R. M.
Laille, E.
Kellerman, A.
Ukrainskyj, S. M.
Dong, Q.
Skikne, B. S.
[J]. LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
[50] A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia
Kunacheewa, Chutima
Thongthang, Pakaporn
Ungprasert, Patompong
Utchariyaprasit, Eakkapol
Owattanapanich, Weerapat
[J]. HEMATOLOGY, 2019, 24 (01) : 498 - 506

← 1 2 3 4 5 →